PD-L1 Single Domain Antibody [F2G2]

PD-L1 Antibody [F2G2] | SD8641 | ProSci

Host: Llama

Reactivity: Human

Homology: N/A

Immunogen: PD-L1 antibody was raised against a recombinant protein corresponding to amino acids 19 - 239 of human PD-L1.

Research Area: Immunology, Cancer, Cell Cycle

Tested Application: E, ICC, IF

Application: PD-L1 antibody can be used for detection of PD-L1 by ELISA, Immunocytochemistry (10 μg/ml) and immunofluorescence (20 μg/ml).

Specificiy: At least three isoforms of PD-L1 are known to exist.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: PD-L1 Antibody is affinity chromatography purified via Nickel column. Antibody is supplied as a His-tagged purified protein.  It also contains a myc-tag for detection.

Clonality: Recombinant Monoclonal

Clone: F2G2

Isotype: sdAb

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PD-L1 Antibody is supplied in PBS.

Concentration: 1 mg/mL

Storage Condition: PD-L1 antibody should be stored in working aliquots at -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: PD-L1 Antibody: B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, B7 homolog 1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.